

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Zhi-Xing Yao et al.	Examiner:	Unknown
Serial No.:	10/663,619	Group Art Unit:	1614
Filed:	September 16, 2003	Docket:	1941.014US1
Title:	Neuroprotective Spirostenol Pharmaceutical Compositions		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Notification to this effect was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004 and October 19, 2004. Thus, Applicant has not included copies of any US Patents or US Patent Applications identifiable by serial number that may be cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

ZHI-XING YAO ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6905

Date June 27, 2006

By Monique M. Berdok Shonka
Monique M. Berdok Shonka
Reg. No. 42,989

CERTIFICATE UNDER 37 C.F.R. 1.8. The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 27th day of June, 2006.

JUDY DENT
Name

Judy Dent
Signature

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Under the Copyright Revision Act of 1976, US PATENT AND TRADEMARK OFFICE is required to report to a collection of information, patents, a notice of copyright notice.

PTO/USPTO/USPTO

Approved for use through 10/2/2005. (USPTO/USPTO)

US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known	
Application Number	10/663,619
Filing Date	September 16, 2003
First Named Inventor	Yao, Zhi-Xing
Group Art Unit	1614
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 1941.014US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date if Appropriate
	US-20060009433A1	01/12/2006	Yao, Z., et al.	01/07/2005
	US-6,593,301	07/15/2003	Ma, B., et al.	06/05/2000

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	†
	DE-4303214A1	08/11/1994	Marks, W.	
	WO-0123408A1	04/05/2004	Barreclough, P., et al.	
	WO-0211708A2	02/14/2004	Niesor, E. J., et al.	
	WO-2006044665A2	04/27/2006	Yao, Z., et al.	
	WO-9916786A1	04/08/1998	Ma, B., et al.	
	WO-9948507A2	08/30/1999	Xia, Zongqin, et al.	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.	†
		BUNDGAARD, H., "Design of Prodrugs", Elsevier Science Publishers, Chapter 1, (1985), 1	
		KEEGAN, B. M., et al., "Multiple Sclerosis", <u>Annual Review of Medicine</u> , 53, (2002), 285-302	
		LECANU, LAURENT, "Identification of naturally occurring spirostenois preventing B-amyloid-induced neurotoxicity", <u>Steroids</u> , 69(1), (Jan., 2004), 1-16	
		LI, H., "Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide", <u>Proceedings of the National Academy of Sciences, USA</u> , (2001), 98:1267-1272	
		ROHER, A E., et al., "Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.", <u>J. Biol. Chem.</u> , 268(5), (Feb. 15, 1993), 3072-3083	
		SHOJI, M., et al., "Distribution of amyloid beta protein precursor in the Alzheimer's disease brain.", <u>Psychiatry and Clinical Neurosciences</u> , 54, (2000), 45-54	
		YAO, ZHI-XING, et al., "22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytotoxicity by binding to beta-amyloid peptide.", <u>Journal of Neurochemistry</u> , 83(5), (Dec., 2002), 1110-1119	
		YAO, Z. X., et al., "Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity", <u>FASEB J.</u> , 16(12), (2002), 1677-9	
		YOUNKIN, S G., "The role of A beta 42 in Alzheimer's disease.", <u>J Physiol Paris</u> , 92(3-4), (1998), 289-292	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO 1449A)

* EXAMINER: Initial reference considered, whether or not citation is in accordance with MPEP 808. Draw the through citation first in accordance and not considered. Include copy of this form with next communication to applicant. Applicant's attention shall be directed to the following: (1) Applicant is to place a check mark here if English language translation is attached.